Hugo Wahnish, Non-Executive Director bought the shares.
A press release sent this morning shows Wahnish purchased ordinary 100,000 shares of 0.1 pence each in Benchmark at a price of GPB 56.5 per share on 9 October 2018.
Following this transaction, Wahnish’s total beneficial interest in the company is 275,000 shares representing approximately 0.05 per cent of the Company’s issued share capital.
- Read more: Benchmark buys data technology firm
Hugo Wahnish was appointed in 2017 and has over 35 years of experience in the animal health and pharmaceuticals industry, including stints with GlaxoSmithKline and Merck.
